Introduction: In-vitro–in-vivo correlation (IVIVC) is a predictive scientific approach that links in vitro dissolution data with in vivo bioavailability and pharmacokinetic responses. IVIVC concepts — including Level A, B, and C correlations, deconvolution, Wagner–Nelson and Loo–Riegelman methods — are central to biopharmaceutics and formulation development. Mastery of IVIVC helps B. Pharm students understand bioavailability, dissolution testing, predictive modeling, regulatory pathways (FDA guidance), and biowaivers. Key keywords: IVIVC, dissolution, bioavailability, deconvolution, predictive model, FDA, BCS, discriminating dissolution, pharmacokinetics. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What is the primary goal of establishing an IVIVC?
- To determine drug toxicity in animals
- To link in vitro dissolution to in vivo bioavailability and predict plasma profiles
- To replace clinical trials for safety assessments
- To measure tablet hardness and friability
Correct Answer: To link in vitro dissolution to in vivo bioavailability and predict plasma profiles
Q2. Which of the following best describes a Level A IVIVC?
- A single-point correlation between one dissolution time and one PK parameter
- A statistical correlation of mean dissolution rates only
- A point-to-point relationship between in vitro dissolution and in vivo input rate over time
- A correlation using only Cmax values
Correct Answer: A point-to-point relationship between in vitro dissolution and in vivo input rate over time
Q3. Which IVIVC level provides the highest predictive confidence for in vivo performance?
- Level C
- Level B
- Level A
- Level D
Correct Answer: Level A
Q4. Which method is commonly used to estimate the fraction of drug absorbed for a one-compartment model?
- Loo–Riegelman method
- Wagner–Nelson method
- Numerical convolution
- Noncompartmental AUC ratio
Correct Answer: Wagner–Nelson method
Q5. The Loo–Riegelman method is specifically applied for which pharmacokinetic situation?
- Zero-order absorption only
- One-compartment models with linear elimination
- Two-compartment models for oral absorption
- Intravenous bolus dosing exclusively
Correct Answer: Two-compartment models for oral absorption
Q6. Which approach is model-independent for deconvolution in IVIVC?
- Compartmental regression
- Wagner–Nelson
- Loo–Riegelman
- Numerical deconvolution
Correct Answer: Numerical deconvolution
Q7. According to regulatory guidance, an acceptable average percent prediction error (PE) for internal validation of IVIVC for AUC and Cmax is generally:
- ≤5%
- ≤10%
- ≤25%
- ≤50%
Correct Answer: ≤10%
Q8. In constructing an IVIVC, which pair is typically plotted to build the correlation?
- Fraction absorbed (Fa) versus plasma clearance (CL)
- Fraction dissolved (Fd) versus fraction absorbed (Fa)
- Dose versus elimination half-life
- Cmax versus time to peak only
Correct Answer: Fraction dissolved (Fd) versus fraction absorbed (Fa)
Q9. Which of the following dissolution apparatus is most commonly used for oral solid dosage IVIVC studies?
- USP Apparatus 7 (reciprocating cylinder)
- USP Apparatus 2 (paddle)
- USP Apparatus 4 (flow-through cell) only
- Microscale dissolution viewer
Correct Answer: USP Apparatus 2 (paddle)
Q10. What is meant by “sink conditions” in dissolution testing?
- When the dissolution vessel is stirred at maximum speed
- When drug concentration in medium is less than about 10–15% of its saturation solubility
- When the tablet sinks to the bottom and does not float
- When pH is maintained at neutral
Correct Answer: When drug concentration in medium is less than about 10–15% of its saturation solubility
Q11. Noyes–Whitney equation is primarily used to describe which phenomenon?
- Plasma protein binding
- Dissolution rate of solid particles
- Hepatic metabolism kinetics
- Renal clearance mechanisms
Correct Answer: Dissolution rate of solid particles
Q12. Which Biopharmaceutics Classification System (BCS) class is most likely suitable for developing a successful IVIVC?
- BCS Class I (high solubility, high permeability)
- BCS Class II (low solubility, high permeability)
- BCS Class III (high solubility, low permeability)
- BCS Class IV (low solubility, low permeability)
Correct Answer: BCS Class II (low solubility, high permeability)
Q13. Which factor most directly reduces the reliability of an IVIVC?
- Linear pharmacokinetics over the studied dose range
- Presence of extensive first-pass metabolism or enterohepatic recirculation
- Using discriminating dissolution conditions
- High in vivo permeability
Correct Answer: Presence of extensive first-pass metabolism or enterohepatic recirculation
Q14. Which metric quantifies the accuracy of predicted pharmacokinetic parameters from IVIVC?
- Percent prediction error (PE)
- Tablet disintegration time
- Potentiometric titration result
- Micromeritics index
Correct Answer: Percent prediction error (PE)
Q15. Level C IVIVC typically correlates which of the following?
- Entire plasma concentration–time profile point-by-point
- Single pharmacokinetic parameters such as Cmax or AUC with a dissolution metric
- Multiple timepoint profiles using deconvolution
- None; Level C is not used in IVIVC
Correct Answer: Single pharmacokinetic parameters such as Cmax or AUC with a dissolution metric
Q16. A multiple Level C IVIVC differs from single-point Level C by:
- Using only one dissolution time point
- Correlating several PK parameters (e.g., Cmax and AUC) with dissolution
- Being equivalent to Level A
- Using animal data only
Correct Answer: Correlating several PK parameters (e.g., Cmax and AUC) with dissolution
Q17. Which statistical parameter is most commonly reported to describe the goodness-of-fit for an IVIVC regression?
- Pearson correlation coefficient (r)
- Coefficient of determination (r²)
- Standard dissolution variance
- Tablet tensile strength
Correct Answer: Coefficient of determination (r²)
Q18. Which in vitro condition enhances the predictive value of dissolution for IVIVC?
- Non-discriminating media that dissolve all formulations identically
- Discriminating dissolution conditions that detect formulation differences
- Using no agitation to simulate stagnant GI tract
- Using extreme pH values only
Correct Answer: Discriminating dissolution conditions that detect formulation differences
Q19. Deconvolution in IVIVC is primarily used to:
- Estimate the drug input or absorption rate from plasma concentration data
- Predict tablet compressibility
- Calculate dissolution apparatus paddle speed
- Measure drug purity
Correct Answer: Estimate the drug input or absorption rate from plasma concentration data
Q20. Which practical application can IVIVC support in regulatory submissions?
- Requesting biowaivers for certain post-approval formulation changes
- Eliminating safety studies for new chemical entities
- Replacing all clinical trials for efficacy
- Predicting excipient toxicity
Correct Answer: Requesting biowaivers for certain post-approval formulation changes
Q21. For a drug with dissolution-limited absorption, which in vitro–in vivo relationship is expected?
- Weak or no correlation between dissolution and absorption
- Strong correlation because in vivo absorption is controlled by dissolution
- Absorption solely controlled by hepatic clearance
- Dissolution independent of formulation factors
Correct Answer: Strong correlation because in vivo absorption is controlled by dissolution
Q22. Which in vitro measure is most often used as the independent variable when establishing IVIVC?
- Percentage of drug dissolved over time (dissolution profile)
- Tablet hardness number
- Melting point of the API
- pH of the gastric fluid only
Correct Answer: Percentage of drug dissolved over time (dissolution profile)
Q23. Which software/approach is commonly used for pharmacokinetic deconvolution and IVIVC modeling?
- WinNonlin (Phoenix) or equivalent PK modeling software
- Microsoft Excel without any statistical tools
- Photo editing software
- Mass spectrometry only
Correct Answer: WinNonlin (Phoenix) or equivalent PK modeling software
Q24. Biorelevant dissolution media are used in IVIVC studies to simulate which conditions?
- In vitro heating profiles
- Fed and fasted gastrointestinal environments
- Sterile intravenous conditions
- Topical skin conditions
Correct Answer: Fed and fasted gastrointestinal environments
Q25. Which experimental prerequisite improves the quality of IVIVC data?
- Using a single in vivo profile from one subject only
- Collecting sufficiently dense plasma sampling during absorption phase
- Omitting assay validation for plasma concentrations
- Using non-discriminatory dissolution media
Correct Answer: Collecting sufficiently dense plasma sampling during absorption phase
Q26. Which type of drug absorption scenario makes a simple IVIVC less likely to succeed?
- Absorption limited strictly by dissolution
- High permeability and dose-independent kinetics
- Transporter-mediated uptake or saturable absorption
- Linear first-order absorption
Correct Answer: Transporter-mediated uptake or saturable absorption
Q27. In IVIVC terminology, the term “fraction absorbed (Fa)” refers to:
- The percentage of the dose that dissolves in vitro
- The cumulative fraction of drug that reaches systemic circulation over time
- The percent of excipient in the formulation
- The fraction of drug that remains undissolved
Correct Answer: The cumulative fraction of drug that reaches systemic circulation over time
Q28. Which experimental design choice can strengthen IVIVC development?
- Testing multiple formulation strengths and dissolution conditions
- Using only one formulation and one dissolution condition
- Avoiding replicate in vivo studies
- Using unrelated animal species only
Correct Answer: Testing multiple formulation strengths and dissolution conditions
Q29. Which statement about Level A IVIVC is TRUE?
- It only correlates a single time point like Cmax
- It can predict the entire plasma profile from in vitro dissolution
- It is the least informative level of correlation
- It cannot be used to support biowaivers
Correct Answer: It can predict the entire plasma profile from in vitro dissolution
Q30. Which outcome is a practical benefit of a validated IVIVC for a marketed product?
- Inability to change manufacturing without new studies
- Setting clinically relevant dissolution specifications and justifying formulation changes without new bioequivalence studies
- Immediate removal of all stability testing
- Requirement for additional invasive sampling in patients
Correct Answer: Setting clinically relevant dissolution specifications and justifying formulation changes without new bioequivalence studies
